EBF3 Antibody

What is EBF3 and why is it significant in research?

EBF3 (Early B-Cell Factor 3) is a transcription factor belonging to the COE family that contains a DNA-binding region with an embedded zinc-finger motif, a dimerization segment, and a Pro/Ser-rich transactivation domain. Its significance stems from its role as a potential tumor suppressor and its critical functions in neural development, bone marrow maintenance, and cell cycle regulation. EBF3 is expressed in normal brain tissue (particularly in cerebellar Purkinje cells and olfactory neurons) but is frequently silenced in various tumors through deletion or methylation of its locus on chromosome 10q26.3 .

What are the key structural characteristics of EBF3 protein that antibodies commonly target?

EBF3 antibodies typically target specific amino acid sequences within the 596 amino acid (human) protein structure. Key regions include:

• DNA-binding domain with embedded zinc-finger motif (aa 51-235)

• Dimerization segment (aa 371-431)

• Pro/Ser-rich transactivation domain (aa 464-555)

Many commercial antibodies target regions like aa 421-470 or aa 399-504, which show high conservation across species, allowing cross-reactivity .

How is EBF3 protein function regulated and what implications does this have for antibody selection?

EBF3 function is regulated through multiple mechanisms including:

• Epigenetic silencing through promoter methylation

• Post-translational modifications

• Protein-protein interactions, particularly homo- and hetero-dimerization with other EBF family members

When selecting antibodies, researchers should consider whether their experimental question requires detection of specific protein-protein interactions or post-translational modifications. For instance, antibodies targeting the dimerization domain may interfere with natural protein interactions, potentially affecting experimental outcomes in co-immunoprecipitation studies .

What are the validated applications for EBF3 antibodies and their associated technical parameters?

EBF3 antibodies have been validated for multiple applications with specific technical parameters:

The optimal antibody concentration should be determined by each laboratory for specific applications .

How should experimental design account for the dual nuclear and cytoplasmic localization of EBF3?

EBF3, as a transcription factor, primarily localizes to the nucleus but can also be found in the cytoplasm under certain conditions. When designing experiments:

• Include proper subcellular fractionation techniques to separate nuclear and cytoplasmic fractions

• Use appropriate nuclear/cytoplasmic markers as controls (e.g., GAPDH for cytoplasm, LaminA for nucleus)

• Consider fixation methods carefully for immunohistochemistry - cross-linking fixatives may mask nuclear epitopes

• When interpreting results, consider that altered localization may indicate functional changes rather than expression changes

Nuclear-cytoplasmic distribution can be effectively assessed using Western blot analysis of separated cellular fractions as demonstrated in studies of EBF3 mutants .

What considerations should be made when selecting EBF3 antibodies for cross-species applications?

When selecting EBF3 antibodies for cross-species applications, consider:

• Sequence homology in the epitope region: Mouse EBF3 shows ~88.8% identity with human EBF3, while regions like aa 399-504 show >99% conservation across species

• Validated cross-reactivity: Some antibodies have confirmed reactivity across multiple species including human, mouse, rat, zebrafish, and Xenopus

• Application-specific validation: An antibody may work for Western blot across species but not for IHC

• Isoform recognition: Consider whether the antibody recognizes known splice variants, such as the nine aa deletion variant between aa 252-260

BLAST analysis can be used to confirm sequence identity across target species before selecting an antibody .

What are common causes of false negative results in EBF3 detection and how can they be addressed?

Common causes of false negative results include:

• Epigenetic silencing: EBF3 is frequently silenced in tumors through promoter methylation. If studying cancer samples, consider:

  • Treating cells with 5-aza-2′-deoxycytidine and trichostatin A to reverse methylation

  • Performing methylation-specific PCR alongside protein detection

  • Using positive control samples with confirmed EBF3 expression

• Protein degradation: EBF3 may be susceptible to degradation during sample preparation. Implement:

  • Use of protease inhibitors

  • Avoidance of repeated freeze-thaw cycles of samples

  • Storage at -70°C rather than -20°C

• Epitope masking: Post-translational modifications or protein-protein interactions may mask epitopes. Try:

  • Multiple antibodies targeting different regions

  • Denaturing conditions for Western blot

  • Antigen retrieval methods for IHC

How can specificity of EBF3 antibodies be validated against other EBF family members?

Validating specificity against other EBF family members is crucial as they share high sequence homology. Recommended approaches include:

• Knockout/knockdown controls: Use EBF3 knockout or siRNA knockdown samples to confirm antibody specificity

• Overexpression systems: Compare cells overexpressing EBF1, EBF2, or EBF3 to assess cross-reactivity

• Peptide competition assays: Pre-incubate antibody with specific peptides from different EBF family members

• Western blot analysis: EBF3 runs at approximately 75 kDa, which may differ slightly from other EBF family members

• Tissue expression pattern comparison: Compare detection patterns with known tissue-specific expression profiles of different EBF family members (e.g., EBF3 has distinctive expression in cerebellar Purkinje cells)

What protocols have been optimized for detecting EBF3 in fixed tissue sections?

For optimal detection of EBF3 in fixed tissue sections:

• Fixation: 4% paraformaldehyde for 24 hours provides good preservation of EBF3 epitopes

• Antigen retrieval: Heat-induced epitope retrieval using citrate buffer (pH 6.0) for 20 minutes

• Blocking: 5% normal serum from the same species as the secondary antibody plus 0.3% Triton X-100

• Primary antibody incubation: Dilution 1:200-1:500, overnight at 4°C

• Detection system: Amplification systems like tyramide signal amplification can enhance sensitivity for low expression levels

• Counterstaining: Light hematoxylin counterstaining preserves visibility of nuclear EBF3 staining

For dual labeling with markers of specific cell types (e.g., cerebellar Purkinje cells), sequential immunostaining protocols have been successfully employed .

How can EBF3 antibodies be employed to investigate its tumor suppressor function across different cancer types?

Advanced approaches to investigate EBF3's tumor suppressor function include:

• Chromatin immunoprecipitation (ChIP) assays: Using EBF3 antibodies to identify direct transcriptional targets involved in cell cycle regulation and apoptosis

  • EBF3 directly binds the p21^cip1/waf1^ promoter and regulates its transcription

  • ChIP-seq can identify global binding patterns across different cancer contexts

• Co-immunoprecipitation studies: Investigating protein-protein interactions with other transcription factors and cell cycle regulators

  • EBF3 may interact with other tumor suppressors or oncogenes depending on the cancer type

• Tissue microarray analysis: Examining EBF3 expression patterns across large cohorts of cancer samples

  • Correlation with clinicopathological features and patient outcomes

  • The table below shows EBF3 expression correlation with clinical variables in pediatric AML:

• Methylation analysis: Combining EBF3 antibody detection with methylation studies to understand epigenetic regulation

  • Aberrant EBF3 methylation was observed in 42.9% (45/105) of pediatric AML samples

What approaches can be used to study EBF3 dimerization and its functional consequences?

Studying EBF3 dimerization requires sophisticated approaches:

• Proximity ligation assays (PLA): Detecting in situ protein-protein interactions between EBF3 and potential dimerization partners (EBF1, EBF2, or EBF3 itself)

• Bimolecular fluorescence complementation (BiFC): Visualizing dimerization in living cells by tagging potential partners with complementary fragments of fluorescent proteins

• FRET-based approaches: Measuring energy transfer between fluorescently labeled EBF3 and partner proteins to confirm direct interaction and determine binding kinetics

• Co-immunoprecipitation with dimerization-specific antibodies: Using antibodies that specifically recognize the EBF3 dimerization domain (aa 371-431)

• Functional assays with dimerization mutants: Comparing transcriptional activity of wild-type EBF3 versus dimerization-deficient mutants using reporter assays

These approaches have revealed that EBF3 can form homodimers or heterodimers with EBF2 or EBF1, with potentially different functional outcomes in gene regulation .

How can EBF3 antibodies contribute to understanding the role of EBF3 in neurodevelopmental disorders?

EBF3 antibodies can be instrumental in understanding neurodevelopmental disorders through:

• Developmental expression profiling: Tracking EBF3 expression throughout embryonic and postnatal brain development using immunohistochemistry

  • Critical for understanding temporal specificity of EBF3 mutations

• Cell-type specific expression analysis: Using co-labeling with neural cell type markers to identify affected populations

  • EBF3 is expressed in cerebellar Purkinje cells and specific neuronal populations

• Assessment of mutant protein function: Comparing localization and expression levels of wild-type versus mutant EBF3 proteins

  • N197D mutation affects nucleoplasmic distribution of EBF3 protein

• Animal model validation: Confirming phenotypic relevance by examining expression in animal models of neurodevelopmental disorders

  • Zebrafish ebf3a mutants show disrupted cerebellar Purkinje cells and lateral line development

• Patient sample analysis: Examining EBF3 expression in available patient samples to correlate with clinical manifestations

  • First case of EBF3 pathogenic mutation associated with HADDS (hypotonia, ataxia, and delayed development syndrome) in Chinese population was recently identified

How should researchers interpret discrepancies between EBF3 mRNA expression and protein detection?

When faced with discrepancies between EBF3 mRNA and protein levels:

• Consider post-transcriptional regulation: EBF3 may be subject to microRNA regulation or RNA binding protein interactions that affect translation efficiency

• Evaluate protein stability: EBF3 protein may undergo regulated degradation through ubiquitin-proteasome pathways

  • Check for proteasome inhibitor effects on protein levels

• Examine methodology sensitivity limits: mRNA detection methods (qPCR, RNA-seq) often have lower detection thresholds than protein methods

• Rule out technical issues:

  • Verify antibody specificity through appropriate controls

  • Consider EBF3 isoforms that may not be detected by all antibodies

  • Check primer specificity for mRNA detection

• Assess subcellular compartmentalization: EBF3 may be sequestered in different cellular compartments affecting extraction and detection efficiency

What statistical approaches are recommended for analyzing EBF3 expression data in clinical samples?

For robust analysis of EBF3 expression in clinical samples:

• Define clear expression categories: Establish objective criteria for categorizing expression as "high" vs "low" based on:

  • Mean or median expression in the cohort

  • Expression in normal control tissues

  • Clinically relevant thresholds determined by ROC analysis

• Appropriate statistical tests:

  • For comparing expression between groups: non-parametric tests (Mann-Whitney U test) as expression data often violates normality assumptions

  • For correlation with continuous variables: Spearman's rank correlation

  • For survival analysis: Kaplan-Meier method with log-rank test and Cox proportional hazards models

• Multiple testing correction: Apply Benjamini-Hochberg or similar methods when testing associations with multiple clinical variables

• Sample size considerations: Conduct power analysis to ensure sufficient sample sizes for detecting clinically meaningful differences

• Multivariate analysis: Include relevant covariates such as age, gender, and disease subtype to identify independent prognostic value

How can researchers integrate EBF3 protein expression data with genomic and epigenomic datasets?

Integration of EBF3 protein data with genomic and epigenomic datasets requires:

• Correlation with methylation status: Compare EBF3 protein levels with promoter methylation data

  • Methylation-specific PCR (MSP) and bisulfite genomic sequencing (BGS) can quantify EBF3 promoter methylation

  • In AML, 42.9% of samples showed aberrant EBF3 methylation by MSP analysis

• Integration with mutation data: Assess impact of EBF3 mutations on protein expression and function

  • Mutations in the DNA-binding domain (DBD) may reduce DNA binding capacity while maintaining protein expression

• ChIP-seq integration: Combine EBF3 protein binding data with gene expression profiles to identify direct transcriptional targets

  • EBF3 overexpression studies identified 93 dysregulated apoptosis-related genes

• Single-cell multi-omics approaches: Correlate EBF3 protein expression with transcriptomic and epigenomic features at single-cell resolution

  • Critical for understanding cellular heterogeneity in complex tissues

• Data visualization frameworks: Employ integrated visualization tools that allow simultaneous viewing of protein, mRNA, and epigenetic data across samples

These integrative approaches can reveal mechanisms underlying EBF3 dysregulation in disease contexts and identify potential therapeutic targets .